For targeting Mcl-1, two Mcl-1 inhibitors are currently being evaluated in ongoing phase I/II clinical trials for different hematological cancers, namely PRT1419 [49] and S64315 (MIK665). This evidence concerns the gene MCL1 and hematopoietic and lymphoid cell neoplasm.